Findings of Misconduct in Science, 16366-16367 [07-1616]

Download as PDF 16366 Federal Register / Vol. 72, No. 64 / Wednesday, April 4, 2007 / Notices Trans No. Acquiring Acquired Entities 20070928 ......................... Aktiegolaget Volvo ............................. Ingersoll-Rand Company Limited ...... 20070932 ......................... Beacon Roofing Supply, Inc .............. 20070940 ......................... OCM Principal Opportunities Fund IV, lL.P. OCM Opportunities Fund VII, L.P ..... Ambassadors international, Inc ......... AP Berry Holdings, LLC .................... Vestar Capital Partners V, L.P .......... Graham Partners II, L.P .................... Apollo Investment Fund VI, L.P ........ Apollo Investment Fund V, L.P ......... Iconix Brand Group, Inc .................... John D. Baker II ................................ Monomoy Capital Partners, L.P ........ North Coast Commercial Roofing Systems, Inc. EXCO Resources, Inc ....................... Blaw-Knox Construction Equipment Corporation. North Coast Commercial Roofing Systems, Inc. EXCO Resources, Inc. 20070944 20070949 20070950 20070951 20070952 20070953 20070954 20070968 20070970 20070971 ......................... ......................... ......................... ......................... ......................... ......................... ......................... ......................... ......................... ......................... 20070974 20070975 20070977 20070982 20070984 ......................... ......................... ......................... ......................... ......................... 20070986 ......................... 20070991 ......................... 20070995 ......................... Zurich Financial Services .................. IDB Holding Corporation Ltd ............. LPL Investment Holdings, Inc ........... Spire Capital Partners II, L.P ............ Marathon Special Opportunity Master Fund, Ltd. CRFRC–D Holdings, Inc ................... Ares Corporate Opportunities Fund, L.P. JLL Partners Fund, V, L.P ................ For Further Information Contact: Sandra M. Peay, Contact Representative or Renee Hallman, Contact Representative. Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H– 303, Washington, DC 20580, (202) 326– 3100. By Direction of the Commission. Donald S. Clark, Secretary. [FR Doc. 07–1646 Filed 4–3–07; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the National Coordinator for Health Information Technology; American Health Information Community Population Health and Clinical Care Connections Workgroup Meeting jlentini on PROD1PC65 with NOTICES Meeting cancellation. 17:57 Apr 03, 2007 Jkt 211001 DEG Acquisitions, LLC ...................... EXCO Resources, Inc ....................... DEG Acquisitions, LLC. EXCO Resources, Inc. Patheon Inc ....................................... Patheon Inc. April 20, 2007, from 10 a.m., to 3:30 p.m. Eastern Daylight Time. ADDRESSES: Hubert H. Humphrey Building (200 Independence Avenue, SW., Washington, DC 20201), Room 505A. Please bring photo ID for entry to a Federal building). FOR FURTHER INFORMATION CONTACT: https://www.hhs.gov/healthit/ahic/ population/. CANCELED DATE/TIME: BILLING CODE 4150–24–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Misconduct in Science SUMMARY: This notice announces the cancellation of the 15th meeting of the American Health Information Community Population Health and Clinical Care Connections Workgroup [formerly Biosurvellance Workgroup] in accordance with the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App.) VerDate Aug<31>2005 Bristol West Holdings, Inc ................. Susan W. Shoval ............................... Pacific Mutual Holding Company ...... Professional Bull Riders, Inc ............. SPX Corporation ............................... EXCO Resources, Inc. Windstar Sail Cruises Limited. Berry Plastics Group, Inc. Huish Detergents, Inc. Berry Plastics Group, Inc. Berry Plastics Group, Inc. Berry Plastics Group, Inc. ROCAWEAR LICENSING, LLC. Holdco. Anchor Hocking CG Operating Company, LLC; Anchor Hocking Operating Company, LLC, Anchor Hocking Operating Company LLC. Bristol West Holdings, Inc. Guard Financial Group, Inc. Pacific Select Group LLC. Professional Bull Riders, Inc. General Signal UK Ltd. Dated: March 27, 2007. Judith Sparrow, Director, American Health Information Community, Office of Programs and Coordination, Office of the National Coordinator for Health Information Technology. [FR Doc. 07–1645 Filed 4–3–07; 8:45 am] BILLING CODE 6750–01–M ACTION: EXCO Resources, Inc ....................... Carnival Corporation ......................... Berry Plastics Group, Inc .................. Paul Danton (Dan) Huish .................. Berry Plastics Group, Inc .................. Berry Plastics Group, Inc .................. Apollo Investment Fund VI, L.P ........ ROCSAN Holdings, LLC ................... Holdco ............................................... Global Home Products LLP, Chapter 11 debtor in possession. Office of the Secretary, HHS. Notice. AGENCY: ACTION: SUMMARY: Notice is hereby given that on March 12, 2007 the Department of Health and Human Services (HHS) Debarring Official, on behalf of the Secretary of HHS, issued a final notice of debarment based on the misconduct PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 in science findings of the U.S. Public Health Service (PHS) in the following case: Rebecca Uzelmeier (formerly known as Rebecca Marcus), Michigan State University: Based on the report of an investigation by Michigan State University (MSU) and additional information obtained by the Office of Research Integrity (ORI) during its oversight review, ORI found that Rebecca Uzelmeier, former doctoral student, Department of Pharmacology and Toxicology, MSU, committed misconduct in science by intentionally and knowingly fabricating and falsifying data in research supported by National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), granted R01 ES02520. ORI issued a charge letter enumerating the above findings of misconduct in science. However, on October 12, 2006, Ms. Uzelmeier filed a request for a hearing under 42 CFR part 93 to dispute these findings before the U.S. Department of Health and Human Services (HHS) Departmental Appeals Board (DAB). On October 19, 2006, ORI moved to dismiss Ms. Uzelmeier’s hearing request because it failed to create a genuine dispute of either material fact or law, as required under 42 CFR 93.504. On March 5, 2007, the Administrative Law Judge (ALJ) with the DAB ruled in ORI’s favor and dismissed Ms. Uzelmeier’s hearing request pursuant to 42 CFR 93.504(a)(2). E:\FR\FM\04APN1.SGM 04APN1 jlentini on PROD1PC65 with NOTICES Federal Register / Vol. 72, No. 64 / Wednesday, April 4, 2007 / Notices The ALJ found that Ms. Uzelmeier’s hearing request raised defenses that either were immaterial to the charges of misconduct in science or that the ALJ had no authority to grant Ms. Uzelmeier’s request for relief under Part 93. Specifically, Ms. Uzelmeier knowingly and intentionally; • Fabricated and falsified data in her research notebook primarily by multiple instances of using data/results generated from one experiment to represent data/ results purportedly obtained from one or more entirely different experiments; and • Fabricated and falsified data in her thesis entitled ‘‘Characterization of the Molecular Mechanism(s) Underlying the Interaction(s) between 2,3,7,8tetrachlorodibenzo-p-Dioxin Mediated and Interferon Gamma Mediated Signal Transduction,’’ including falsifying and fabricating autoradiographic films, computer image files scanned from those films, numerical data reduced from those computer files, documentation of those results in her black three-ring binder, and data in associated multiple figures and projection slides. Ms. Uzlmeier’s research concerned the interaction between the environmental toxin, dioxin, and a cytokine, interferon, on cellular signaling in the immune system. The approach was to exploit dioxin, or ‘‘TCDD’’ (2,3,7,8-tetrachlorodibenzo-pdioxin), as a probe that suppresses the immune system to delineate a role for the aryl hydrocarbon receptor protein (AhR), which is a cytosolic receptor that can be transported to the nucleus to also act as a nuclear transcription factor. The specific aim was to determine whether the mechanism of action of a naturally occurring regulatory factor, interferon-g (IFN-g), to antagonize the immunosuppressive actions of dioxin, was through reduced AhR signaling. Ms. Uzelmeier’s actions caused the withdrawal of a manuscript that had been submitted for publication, the withdrawal of her mentor’s PHS grant application, and her dismissal from graduate school. The following administrative actions have been implemented for a period of five (5) years, beginning on March 12, 2007: (1) Ms. Uzelmeier has been debarred from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as ‘‘covered transactions’’ as defined in the VerDate Aug<31>2005 17:57 Apr 03, 2007 Jkt 211001 debarment regulations at 2 CFR 180 and 376; and (2) Ms. Uzelmeier is prohibited from serving in any advisory capacity to PHS including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as consultant. FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. Chris B. Pascal, Director, Office of Research Integrity. [FR Doc. 07–1616 Filed 4–3–07; 8:45 am] BILLING CODE 4160–17–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Healthcare Research and Quality Solicitation for Nominations for Members of the U.S. Preventive Services Task Force Agency for Healthcare Research and Quality (AHRQ), HHS. ACTION: Solicits nominations for new members. AGENCY: SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) invites nominations of individuals qualified to serve as members of the U.S. Preventive Services Task Force (the Task Force). The Task Force, a standing, independent panel of private-sector experts in prevention and primary care, is composed of members appointed to serve for four-year terms with an option for reappointment. New members are selected each year to replace (approximately) one fourth of the Task Force members, i.e., those who are completing their appointments. Individuals nominated but not appointed in previous years, as well as those newly nominated, are considered in the annual selection process. Task Force members meet three times a year for two days in the Washington, DC area. Member duties include reviewing and preparing comments (off site) on systematic evidence reviews prior to discussing and making recommendations on preventive services, drafting final recommendation documents, and participating in workgroups on specific topics or methods. AHRQ particularly encourages nominations of women, members of minority populations, and persons with disabilities. Interested individuals can self nominate. Organizations and individuals may nominate one or more PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 16367 persons qualified for membership on the Task Force. Qualification Requirements: The mission of the Task Force is to produce evidence-based recommendations on the appropriate screening, counseling, and provision of preventive medication for asymptomatic patients seen in the primary care setting. Therefore, in order to qualify for the Task Force, an applicant or nominee MUST demonstrate the following: 1. Knowledge and experience in the critical evaluation of research published in peer reviewed literature and in the methods of evidence review; 2. Understanding and experience in the application of synthesized evidence to clinical decision-making and/or policy; 3. Expertise in disease prevention and health promotion; 4. Ability to work collaboratively with peers; and, 5. Clinical expertise in the primary health care of children and/or adults, and/or expertise in counseling and behavioral interventions for primary care patients. Some Task Force members without primary health care clinical experience may be selected based on their expertise in methodological issues such as medical decision making, clinical epidemiology, behavioral medicine, and health economics. Strongest consideration will be given to individuals who are recognized nationally or intentionally for scientific leadership within their field of expertise. Applicants must have no substantial conflicts of interest that would impair the scientific integrity of the work of the Task Force including financial, intellectual, or other conflicts. DATES: All nominations submitted in writing or electronically, and received by Thursday, May 31, 2007, will be considered for appointment to the Task Force. Nominated individuals will be selected for the Task Force on the basis of their qualifications (in particular, those that address the required qualifications, outlined above) and the current expertise needs of the Task Force. It is anticipated that 4 individuals will be invited to serve on the Task Force beginning in January, 2008. AHRQ will retain and consider for future vacancies the nominations of those not selected during this cycle. ADDRESSES: Submit your responses either in writing or electronically to: Gloria Washington, ATTN: USPSTF Nominations, Center for Primary Care, Prevention, and Clinical Partnerships, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, E:\FR\FM\04APN1.SGM 04APN1

Agencies

[Federal Register Volume 72, Number 64 (Wednesday, April 4, 2007)]
[Notices]
[Pages 16366-16367]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-1616]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Misconduct in Science

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that on March 12, 2007 the Department 
of Health and Human Services (HHS) Debarring Official, on behalf of the 
Secretary of HHS, issued a final notice of debarment based on the 
misconduct in science findings of the U.S. Public Health Service (PHS) 
in the following case:
    Rebecca Uzelmeier (formerly known as Rebecca Marcus), Michigan 
State University: Based on the report of an investigation by Michigan 
State University (MSU) and additional information obtained by the 
Office of Research Integrity (ORI) during its oversight review, ORI 
found that Rebecca Uzelmeier, former doctoral student, Department of 
Pharmacology and Toxicology, MSU, committed misconduct in science by 
intentionally and knowingly fabricating and falsifying data in research 
supported by National Institute of Environmental Health Sciences 
(NIEHS), National Institutes of Health (NIH), granted R01 ES02520.
    ORI issued a charge letter enumerating the above findings of 
misconduct in science. However, on October 12, 2006, Ms. Uzelmeier 
filed a request for a hearing under 42 CFR part 93 to dispute these 
findings before the U.S. Department of Health and Human Services (HHS) 
Departmental Appeals Board (DAB). On October 19, 2006, ORI moved to 
dismiss Ms. Uzelmeier's hearing request because it failed to create a 
genuine dispute of either material fact or law, as required under 42 
CFR 93.504. On March 5, 2007, the Administrative Law Judge (ALJ) with 
the DAB ruled in ORI's favor and dismissed Ms. Uzelmeier's hearing 
request pursuant to 42 CFR 93.504(a)(2).

[[Page 16367]]

The ALJ found that Ms. Uzelmeier's hearing request raised defenses that 
either were immaterial to the charges of misconduct in science or that 
the ALJ had no authority to grant Ms. Uzelmeier's request for relief 
under Part 93.
    Specifically, Ms. Uzelmeier knowingly and intentionally;
     Fabricated and falsified data in her research notebook 
primarily by multiple instances of using data/results generated from 
one experiment to represent data/results purportedly obtained from one 
or more entirely different experiments; and
     Fabricated and falsified data in her thesis entitled 
``Characterization of the Molecular Mechanism(s) Underlying the 
Interaction(s) between 2,3,7,8-tetrachlorodibenzo-p-Dioxin Mediated and 
Interferon Gamma Mediated Signal Transduction,'' including falsifying 
and fabricating autoradiographic films, computer image files scanned 
from those films, numerical data reduced from those computer files, 
documentation of those results in her black three-ring binder, and data 
in associated multiple figures and projection slides.
    Ms. Uzlmeier's research concerned the interaction between the 
environmental toxin, dioxin, and a cytokine, interferon, on cellular 
signaling in the immune system. The approach was to exploit dioxin, or 
``TCDD'' (2,3,7,8-tetrachlorodibenzo-p-dioxin), as a probe that 
suppresses the immune system to delineate a role for the aryl 
hydrocarbon receptor protein (AhR), which is a cytosolic receptor that 
can be transported to the nucleus to also act as a nuclear 
transcription factor. The specific aim was to determine whether the 
mechanism of action of a naturally occurring regulatory factor, 
interferon-[gamma] (IFN-[gamma]), to antagonize the immunosuppressive 
actions of dioxin, was through reduced AhR signaling.
    Ms. Uzelmeier's actions caused the withdrawal of a manuscript that 
had been submitted for publication, the withdrawal of her mentor's PHS 
grant application, and her dismissal from graduate school.
    The following administrative actions have been implemented for a 
period of five (5) years, beginning on March 12, 2007:
    (1) Ms. Uzelmeier has been debarred from any contracting or 
subcontracting with any agency of the United States Government and from 
eligibility or involvement in nonprocurement programs of the United 
States Government referred to as ``covered transactions'' as defined in 
the debarment regulations at 2 CFR 180 and 376; and
    (2) Ms. Uzelmeier is prohibited from serving in any advisory 
capacity to PHS including but not limited to service on any PHS 
advisory committee, board, and/or peer review committee, or as 
consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. 07-1616 Filed 4-3-07; 8:45 am]
BILLING CODE 4160-17-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.